These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28284234)

  • 1. Humoral immune system targets clonotypic antibody-associated hepatitis C virus.
    Naik AS; Palmer BA; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Gen Virol; 2017 Feb; 98(2):179-189. PubMed ID: 28284234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses.
    Palmer BA; Schmidt-Martin D; Dimitrova Z; Skums P; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Virol; 2015 Dec; 90(7):3318-29. PubMed ID: 26719263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.
    Naik AS; Owsianka A; Palmer BA; O'Halloran CJ; Walsh N; Crosbie O; Kenny-Walsh E; Patel AH; Fanning LJ
    PLoS One; 2017; 12(5):e0175349. PubMed ID: 28558001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.
    von Hahn T; Yoon JC; Alter H; Rice CM; Rehermann B; Balfe P; McKeating JA
    Gastroenterology; 2007 Feb; 132(2):667-78. PubMed ID: 17258731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
    Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
    J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
    Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L
    Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
    Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A possible role of hypervariable region 1 quasispecies in escape of hepatitis C virus particles from neutralization.
    Korenaga M; Hino K; Katoh Y; Yamaguchi Y; Okuda M; Yoshioka K; Okita K
    J Viral Hepat; 2001 Sep; 8(5):331-40. PubMed ID: 11555190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Timms JM; McClure CP; Brown RJ; Hickling TP; Pietschmann T; Bartenschlager R; Patel AH; Ball JK
    Hepatology; 2006 Mar; 43(3):592-601. PubMed ID: 16496330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
    Wasilewski LN; Ray SC; Bailey JR
    J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.
    Owsianka A; Tarr AW; Juttla VS; Lavillette D; Bartosch B; Cosset FL; Ball JK; Patel AH
    J Virol; 2005 Sep; 79(17):11095-104. PubMed ID: 16103160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
    Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
    Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.